Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-31,600
Closed -$939K 1348
2025
Q2
$939K Hold
31,600
﹤0.01% 1554
2025
Q1
$965K Hold
31,600
﹤0.01% 1626
2024
Q4
$1.25M Hold
31,600
﹤0.01% 1738
2024
Q3
$1.23M Hold
31,600
﹤0.01% 1712
2024
Q2
$1.33M Hold
31,600
﹤0.01% 1787
2024
Q1
$927K Hold
31,600
﹤0.01% 1800
2023
Q4
$1.15M Buy
+31,600
New +$1.04M ﹤0.01% 1847
2023
Q2
Sell
-63,000
Closed -$1.44M 2106
2023
Q1
$1.44M Buy
63,000
+16,700
+36% +$430K ﹤0.01% 1962
2022
Q4
$1.58M Buy
46,300
+26,500
+134% +$888K ﹤0.01% 2001
2022
Q3
$602K Buy
+19,800
New +$679K ﹤0.01% 2042
2015
Q3
Sell
-64,100
Closed -$1.5M 2325
2015
Q2
$1.5M Hold
64,100
﹤0.01% 2082
2015
Q1
$1.67M Hold
64,100
﹤0.01% 2104
2014
Q4
$1.42M Hold
64,100
﹤0.01% 2142
2014
Q3
$1.16M Sell
64,100
-64,100
-50% -$1.28M ﹤0.01% 2186
2014
Q2
$2.75M Buy
128,200
+64,100
+100% +$1.37M ﹤0.01% 2131
2014
Q1
$1.45M Buy
+64,100
New +$1.57M ﹤0.01% 2062

Other funds holding SRDX

Norges Bank's SRDX Position: Q3 2025 in Review

Norges Bank sold out of Surmodics (SRDX) in Q3 2025, closing a stake of 31,600 shares — an estimated $939K sold.

Norges Bank first reported a position in SRDX in Q1 2014 and held it in 16 quarters. The position peaked at $2.75M in Q2 2014. 146 funds tracked by Wall St. Rank hold SRDX as of Q3 2025.

  • Norges Bank reported no remaining Surmodics position as of Q3 2025 after selling out during the quarter.
  • Norges Bank sold 31,600 Surmodics shares in Q3 2025, an estimated $939K.
  • Norges Bank first reported a position in Surmodics in Q1 2014 and held it in 16 quarters.
  • Norges Bank's Surmodics position peaked at $2.75M in Q2 2014.
  • 146 funds tracked by Wall St. Rank held Surmodics as of Q3 2025.

Based on Norges Bank's 13F filing for Q3 2025.